Clinical Trial

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 26, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-11.
Trial Details
NCT Number NCT06177015
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy
Enrollment 200 participants
Start Date 2023-12-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-12-26